Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 16/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841923 | 0.94 | TSHR (0.54) | NAMPTSMN1; SMN2L3MBTL1ITGB3ITGAV | |
| SCHEMBL2832005 | 0.93 | NAMPT (0.59) | NAMPTHDAC1 | |
| SCHEMBL2842099 | 0.93 | NAMPT (0.50) | NAMPTHDAC1ITGB3ITGAV | |
| SCHEMBL2833586 | 0.92 | NAMPT (0.52) | NAMPTHDAC1SMN1; SMN2L3MBTL1ITGB3 | |
| SCHEMBL2836738 | 0.91 | NAMPT (0.59) | NAMPTSMN1; SMN2ITGB3ITGAV | |
| SCHEMBL2834348 | 0.88 | NAMPT (0.59) | NAMPTHDAC1 | |
| SCHEMBL2833783 | 0.87 | ITGB3 (0.53) | NAMPTSMN1; SMN2ITGB3ITGAVTSHR | |
| SCHEMBL2833096 | 0.86 | NAMPT (0.46) | NAMPTSMN1; SMN2L3MBTL1ITGB3ITGAV | |
| SCHEMBL2836392 | 0.85 | TSHR (0.52) | NAMPTHDAC1SMN1; SMN2L3MBTL1ITGB3 | |
| SCHEMBL2841975 | 0.85 | NAMPT (0.49) | NAMPTHDAC1ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2003-07-31 | — | — | US | claimed |
| EP-1282602-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Italia S.p.A. (IT) | 2003-02-12 | — | — | EP | claimed |
| WO-2001087840-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-11-22 | — | — | WO | claimed |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2730282-A1 | Methods and compositions for the treatment of proteinuric diseases | The General Hospital Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-6974828-B2 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2005-12-13 | — | — | US | disclosed |
| EP-1282602-B1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA SPA (IT) | 2005-09-21 | — | — | EP | disclosed |
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2003-07-31 | — | — | US | disclosed |
| EP-1282602-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Italia S.p.A. (IT) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001087840-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | NAMPT 357/4885HDAC1 2174/4885SMN1; SMN2 2933/4885 |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | NAMPT 357/4885HDAC1 2174/4885SMN1; SMN2 2933/4885 |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | ITGB3, PLAUR, PROC | NAMPT 357/4885HDAC1 2174/4885SMN1; SMN2 2933/4885 |
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | ITGB3, HCAR3, ADRB3 | NAMPT 3667/4885HDAC1 3299/4885SMN1; SMN2 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.